Introduction
============

Hearing impairment is the most common neurosensory disorder in humans. The reported incidence varies from 1 in 300 to 1 in 1000 children \[[@B1]-[@B4]\]. Approximately half of cases have a genetic etiology, including syndromic and non-syndromic forms, with extraordinary genetic heterogeneity. Non-syndromic deafness accounts for 60--70% of inherited hearing impairment. It involves more than 100 different genes with autosomal dominant (DFNA), autosomal recessive (DFNB), X-linked (DFN), and maternal inheritance \[[@B5]\], with autosomal recessive being the most common. For many populations, the most common cause for non-syndromic autosomal recessive hearing loss is mutated Connexin 26, a gap junction protein encoded by the *GJB2*gene (MIM 121011) \[[@B6]-[@B13]\]. There are a few specific mutations in *GJB2*gene that are associated with the autosomal dominant syndromic forms of deafness, and typically present with skin abnormalities including keratitis-ichthyosis \[[@B14]-[@B16]\].

Connexins are transmembrane proteins. Six monomers of connexin proteins associate to form a transmembrane hexameric gap junction hemi-channel called a connexon. Connexons embedded in the surfaces of adjacent cells associate to form an intercellular channel \[[@B17],[@B18]\]. In the inner ear, connexin 26 can be in association with other connexins to form heteromeric connexons. Gap junction channels can be homotypic or heterotypic. Connexin 26 gap junction channels recycle potassium ions as part of a mechanism of auditory signal transduction in inner ear \[[@B19]\].

Mutations in three connexin (Cx) genes, *GJB2*(Cx26), *GJB6*(Cx30), and *GJB3*(Cx31), have been identified and are known to cause hearing impairment \[[@B18],[@B19]\]. Sequence analysis of the *GJB2*gene in subjects with autosomal recessive hearing impairment revealed that a high number of patients carried only one mutant allele. Some of these families showed clear evidence of linkage to the DFNB1 locus, which contains two genes, *GJB2*and *GJB6*\[[@B6],[@B20]\]. Further analysis demonstrated that some *GJB2*heterozygotes also carried a truncating deletion of the *GJB6*gene, encoding connexin 30, in *trans*\[[@B21],[@B22]\].

To date, more than 150 mutations, polymorphisms, and unclassified variants have been described in the *GJB2*gene <http://davinci.crg.es/deafness>. The mutation spectrum and prevalence of mutations vary significantly among different ethnic groups. Three mutations, c.35delG, c.167delT, and c.235delC, are found to be the most frequent mutations in Caucasian, Ashkenazi Jewish, and Asian populations, respectively \[[@B6],[@B7],[@B9]-[@B13],[@B20],[@B23]-[@B26]\].

In China, it is estimated that 30,000 babies are born with congenital hearing impairment every year \[[@B27]\]. The mutation spectrum of the *GJB2*gene in Chinese patients with nonsyndromic hearing impairment (NSHI) has not been analyzed. Our recent study by screening for just the most common mutation, c.235delC, in 3004 Chinese NSHI patients revealed that 488 (16.3%) patients carried at least one c.235delC mutant allele, with 233 (7.8%) homozygotes and 255 (8.5%) heterozygotes \[[@B28]\], though the frequencies of homozygote and heterozygote of c.235delC varied from 0% to 14.7% and from 1.7% to 16.1% respectively in the populations examined in this study. Among different Chinese sub-ethnic groups the c.235delC allele frequency was the lowest (0.8%) in the Tibetan and the highest (31.0%) in Maan. These results highlight the need to sequence the entire *GJB2*gene in order to more accurately establish the actual mutation frequency and mutation spectrum of *GJB2*gene within various Chinese sub-populations. Our preliminary results reveal that other *GJB2*mutations account for an additional 7.1% of NSHI patients from Qinghai, where only 7.1% patients carried at least one c.235delC mutation. Nevertheless, sequencing analysis of the entire coding region of the *GJB2*gene in patients from Guangxi where the frequency of the c.235delC mutation is 3.4% reveals only one other mutation in 87 deaf patients. These results have two important implications: that the *GJB2*gene needs to be sequenced in its entirety; and that mutations in genes responsible for NSHI other than *GJB2*should be searched in patients who do not harbor two mutant alleles in the *GJB2*gene. In this study, we report the results of sequencing the *GJB2*gene in 2063 patients with NSHI from 23 different regions of China (Figure [1](#F1){ref-type="fig"}).

![**Geographic distribution and the proportion of patients carrying at least one *GJB2*mutant allele in each region studied**.](1479-5876-7-26-1){#F1}

Materials and methods
=====================

Patients and DNA samples
------------------------

A total of 2063 unrelated NSHI students from 23 different regions of China were included in this sequencing study. The selection of samples was random regardless of the c.235delC genotype. The patients consisted of 1179 males and 884 females ranging in age from 2 to 30 years with an average age of 13.7 ± 4.5. The majority of patients were Han Chinese (1640), followed by Tibetan (122), minorities in the Southwest region (119), Hui (79), minorities in Xinjiang (62), Mongolian (21), Maan (18) and Korean (2). Ethnic subgroup designations were based on permanent residency documentation.

This study was performed according to a protocol approved by the ethics committee of the Chinese PLA General Hospital. The subjects in this study were from deaf schools of each region and were recently described \[[@B28]\]. Only the unrelated patients with nonsyndromic hearing loss were included in this study. Parents were not included in this study. All patients showed moderate to profound bilateral sensorineural hearing impairment on audiograms and no pathient with mild hearing impairment was found in this cohort. In addition to the 2063 patients, 301 Han control individuals with normal hearing (either evaluated by pure tone audiometry or by self-assessment) from Beijing Capital (Northern) and Jiangsu Province (Eastern), two densely populated regions consisting of 98% Han Chinese, were also analyzed. DNA was extracted from peripheral blood leukocytes using a commercially available DNA extraction kit (Watson Biotechnologies Inc, Shanghai, China).

Sequence analysis
-----------------

The coding exon (Exon2) and flanking intronic regions of *GJB2*gene were PCR amplified with forward primer 5\'TTGGTGTTTGCTCAGGAAGA 3\' and reverse primer 5\'GGCCTACAGGGGTTTCAAAT 3\'. Among this study cohort, 851 patients from central China were also analyzed for mutations in Exon1 and flanking introns by PCR/sequencing. The PCR primers used are forward primer: 5\'CTCATGGGGGCTCAAAGGAACTAGGAGATCGG3\' and reverse primer 5\'GGGGCTGGACCAACACACGTCCTTGGG3\'. The PCR products were purified on Qia-quick spin columns (Qiagen, Valencia, CA) and sequenced using the BigDye Terminator Cycle Sequencing kit (version v3.1) and ABI 3130 automated DNA sequencers (Applied Biosystems, Foster City, CA, USA,) with Sequence Analysis Software (Sequencing Analysis version 3.7). DNA sequence variations were identified by comparison of subject DNA sequence to *GJB2*reference sequences, Genebank Accession Number [AY280971](AY280971). Numbering of *GJB2*begins with the nucleotide A of the ATG start codon in Exon2 as cDNA position number 1. The sequences were analyzed using Genetool Lite software and the *GJB2*Genebank sequence. The presence of 309 kb deletion of *GJB6*was analyzed by PCR method \[[@B21],[@B22]\]. A positive control of this deletion provided by Balin Wu (Department of Laboratory Medicine, Children\'s Hospital and Harvard Medical School, USA.) was used for the detection of deletion in *GJB*6 gene.

Statistical analysis
--------------------

The statistical analysis was performed using SAS 9.1.3 software (SAS, Cary, North Carolina, USA).

Results
=======

Mutations in *GJB2*gene
-----------------------

Sequencing of the coding region of the *GJB2*gene revealed that at least 104 different genotypes were found in the 2063 patients (Table [1](#T1){ref-type="table"}). Among them, 64 different genotypes harboring pathogenic mutations were found in 432 patients (Table [1](#T1){ref-type="table"}). Three hundred and seven patients had two confirmed pathogenic mutations, including 178 homozygotes and 129 compound heterozygotes. One hundred twenty five patients carried one heterozygous pathogenic mutation without an identified second mutant allele. Thus, *GJB2*mutant alleles account for 17.9% (739/4126) of the total alleles in 2063 NSHI patients. The most common genotype was homozygous c.235delC, followed by compound heterozygosity for c.235delC/c.299_300delAT, which accounted for 8.0% (164/2063) and 3.2% (66/2063) of NSHI patients respectively. The most common mutation c.235delC was in compound heterozygosity with 14 other different pathogenic mutations in 113 patients, and was present as a single heterozygous mutant allele in 68 patients. In addition, there were 23 different genotypes in patients carrying one allele of unclassified variants (Table [1](#T1){ref-type="table"}). Twenty-three alterations were found, five (p.W3X, c.99delT, c.155_c.158delTCTG, p.Y152X, and c.512_c.513insAACG) of them were novel and pathogenic, and twelve (p,G21R, p,I30F, p.F31L, p.V37I, p.V63L, p.T123N, p.V153A, p.D159N, p.F191L, p.M195V, p.V198M, and p.I215N) are unclassified variants (Table [1](#T1){ref-type="table"} and Supplemental Table 1). The distribution of various genotypes in 23 regions (Figure [1](#F1){ref-type="fig"}) is detailed in Table [2](#T2){ref-type="table"} and Supplemental Table 2. The frequencies of the three most common *GJB2*mutations in the 23 regions studied are listed in Table [2](#T2){ref-type="table"}. The allele frequency of all mutations in the *GJB2*gene in NSHI patients varied from 4.0% in Guangxi to 30.4% in Jiangsu (Table [2](#T2){ref-type="table"}). Regions which appeared to have a higher frequency of the c.235delC mutation (Jiangsu, Inner Mongolia, Beijing, Hebei, Shanghai) also had a relatively high frequency of other *GJB2*mutations (eg, the frequency of the c.235delC mutation in Jiangsu was as high as 20.6% and the frequencies of other mutations were also as high as 9.8%). Similarly, regions such as Shaanxi and Guangxi where the frequency of the c.235delC mutation is low (5.8 and 3.4% respectively), also had lower frequencies of other mutations (1.9 and 0.6% respectively). Patients from Tibet, Yunnan, Xinjiang, Heilongjiang, and Ningxia appear to have the most diverse mutation spectrum because uncommon mutations (except c.235delC, c.299_c.300delAT and c.176_c.191del16) comprise 84.2, 30.8, 26.1, 21.4, and 20.4%, respectively of overall *GJB2*mutations in those regions.

###### 

*GJB2*genotypes of 2063 Chinese NSHI patients

  Allele 1                                Allele 2                                                                                                                                                                               
  --------------------------------------- ---------------------------------- ---------------------------- ------------ -------------------------------- ---------------------------------- ---------------------------- -------- -----------------------
  nucleotide change                       consequence or amino acid change   category                     domain       nucleotide change                consequence or amino acid change   Category                     domain   Number of patients^d^
                                                                                                                                                                                                                                 
  homozygous                                                                                                                                                                                                                     
  c.35delG                                frame-shift                        pathogenic                   NT           c.35delG                         frame-shift                        Pathogenic                            2
  c.176_c.191del16                        fram shift                         pathogenic                   EC1          c.176_c.191del16                 frame-shift                        Pathogenic                   EC1      2
  c.235delC                               frame-shift                        pathogenic                   TM2          c.235delC                        frame-shift                        Pathogenic                   TM2      164
  c.299_c.300delAT                        frame-shift                        pathogenic                   CL           c.299_c.300delAT                 frame-shift                        pathogenic                   CL       8
  c.512_c.513insAACG                      frame-shift                        pathogenic                   EC2          c.512_c.513insAACG               frame-shift                        pathogenic                   EC2      1
  c.605_c.606ins46                        frame-shift                        pathogenic                   TM4          c.605_c.606ins46                 frame-shift                        pathogenic                   TM4      1
                                                                                                                                                                                                                                 
  compound heterozygous                                                                                                                                                                                                          
  c.9G\>A, c.79G\>A                       p.W3X, p.V27I                      pathogenic, polymophism      NT, TM1      c.427C\>T                        p.R143W                            pathogenic                   TM3      1
  c.35delG                                frame-shift                        pathogenic                   NT           c.299_c.300delAT                 frame-shift                        pathogenic                   CL       1
  c.35delG                                frame-shift                        pathogenic                   NT           c.313_c.326del14                 frame-shift                        pathogenic                   CL       1
  c.176_c.191del16                        frame-shift                        pathogenic                   EC1          c.9G\>A, c.79G\>A                p.W3X, p.V27I                      pathogenic, polymophism      NT+TM1   2
  c.176_c.191del16                        frame-shift                        pathogenic                   EC1          c.299_c.300delAT                 frame-shift                        pathogenic                   CL       4
  c.176_c.191del16                        frame-shift                        pathogenic                   EC1          c.388_c.397del10                 frame-shift                        pathogenic                            1
  c.235delC                               frame-shift                        pathogenic                   TM2          c.9G\>A, c.79G\>A                p.W3X, p.V27I                      pathogenic, polymophism      NT+TM1   2
  c.235delC                               frame-shift                        pathogenic                   TM2          c.35delG                         frame-shift                        pathogenic                   NT       1
  c.235delC                               frame-shift                        pathogenic                   TM2          c.35insG                         frame-shift                        pathogenic                   NT       2
  c.235delC                               frame-shift                        pathogenic                   TM2          c.94C\>T                         p.R32C                             pathogenic                   TM1      1
  c.235delC                               frame-shift                        pathogenic                   TM2          c.99delT                         frame-shift                        pathogenic                   TM1      1
  c.235delC                               frame-shift                        pathogenic                   TM2          c.139G\>T                        p.E47X                             pathogenic                   EC1      3
  c.235delC                               frame-shift                        pathogenic                   TM2          c.155_c.158delTCTG               frame-shift                        pathogenic                   EC1      2
  c.235delC                               frame-shift                        pathogenic                   TM2          c.176_191del16                   frame-shift                        pathogenic                   EC1      18
  c.235delC                               frame-shift                        pathogenic                   TM2          c.257C\>G                        p.T86R                             pathogenic                   TM2      6
  c.235delC                               frame-shift                        pathogenic                   TM2          c.299_c.300delAT                 frame-shift                        pathogenic                   CL       65
  c.235delC                               frame-shift                        pathogenic                   TM2          c.299_c.300delAT, c.79G\>A       frame-shift, p.V27I                frame-shift, polymorphism    CL+TM1   1
  c.235delC                               frame-shift                        pathogenic                   TM2          c.313_c.326del14                 frame-shift                        pathogenic                   CL       1
  c.235delC                               frame-shift                        pathogenic                   TM2          c.427C\>T                        p.R143W                            pathogenic                   TM3      3
  c.235delC                               frame-shift                        pathogenic                   TM2          c.512_c.513insAACG               frame-shift                        pathogenic                   EC2      6
  c.235delC                               frame-shift                        pathogenic                   TM2          c.605_c.606ins46                 frame-shift                        pathogenic                   TM4      1
  c.299_c.300delAT                        frame-shift                        pathogenic                   CL           c.139G\>A                        p.E47K                             pathogenic                   EC1      1
  c.299_c.300delAT                        frame-shift                        pathogenic                   CL           c.257C\>G                        p.T86R                             pathogenic                   TM2      1
  c.299_c.300delAT                        frame-shift                        pathogenic                   CL           c.512_c.513insAACG               frame-shift                        pathogenic                   EC2      3
  c.456C\>A                               p.Y152X                            pathogenic                   TM3, CL      c.380G\>A, c.79G\>A, c.341A\>G   p.R127H, p.V27I, E114G             pathogenic, polymophism      TM1+CL   1
                                                                                                                                                                                                                                 
  heterozygous (one mutant allele only)                                                                                                                                                                                          
  c.11G\>A                                p.G4D                              pathogenic                   NT           c.109G\>A                        p.V37I                             see note                     TM1      1
  c.11G\>A                                p.G4D                              pathogenic                   NT           Nv                                                                                                        2
  c.35delG                                frame-shift                        pathogenic                   NT           c.79G\>A, c.341A\>G              p.V27I p,E114G                     polymorphism                 TM1+CL   1
  c.35delG                                frame-shift                        pathogenic                   NT           Nv                                                                                                        4
  c.155_c.158delTCTG                      frame-shift                        pathogenic                   EC1          c.341A\>G, c.644T\>A             p.E114G, p.I215N                   polymorphism, unclassified   CL+CT    1
  c.176_c.191del16                        frame-shift                        pathogenic                   EC1          Nv                                                                                                        2
  c.235delC                               frame-shift                        pathogenic                   TM2          c.109G\>A                        p.V37I                             see note                     TM1      11
  c.235delC                               frame-shift                        pathogenic                   TM2          c.79G\>A                         p.V27I                             polymorphism                 TM1      6
  c.235delC                               frame-shift                        pathogenic                   TM2          c.79G\>A, c.341A\>G              p.V27I, p.E114G                    polymorphism                 TM1+CL   5
  c.235delC                               frame-shift                        pathogenic                   TM2          c.341A\>G                        p.E114G                            polymorphism                 CL       2
  c.235delC                               frame-shift                        pathogenic                   TM2          c.558G\>A                        p.T186T                            polymorphism                 EC2      1
  c.235delC                               frame-shift                        pathogenic                   TM2          Nv                                                                                                        43
  c.253T\>C                               p.S85P                             pathogenic                   TM2          Nv                                                                                                        1
  c.299_c.300delAT                        frame-shift                        pathogenic                   CL           c.109G\>A                        p.V37I                             see note                     TM1      1
  c.299_c.300delAT                        frame-shift                        pathogenic                   CL           c.79G\>A, c.341A\>G              p.V27I, p.E114G                    polymorphism                 TM1+CL   1
  c.299_c.300delAT                        frame-shift                        pathogenic                   CL           Nv                                                                                                        4
  c.380G\>A, c.341A\>G                    p.R127H, p.E114G                   pathogenic, polymophism      CL+CL        c.109G\>A                        p.V37I                             see note                     TM1      1
  c.380G\>A                               p.R127H                            pathogenic                   CL           c.109G\>A                        p.V37I                             see note                     TM1      1
  c.380G\>A, c.109G\>A                    p.R127H, p.V37I                    pathogenic, polymophism      TM1+CL       c.79G\>A                         p.V27I                             polymorphism                 TM1      1
  c.380G\>A, c.79G\>A                     p.R127H, p.V27I                    pathogenic, polymophism      TM1+CL       c.79G\>A, c.341A\>G              p.V27I, p.E114G                    polymorphism                 TM1+CL   1
  c.380G\>A                               p.R127H                            pathogenic                   CL           c.79G\>A, c.341A\>G              p.V27I, p.E114G                    polymorphism                 TM1+CL   9
  c.380G\>A, c.147C\>T                    p.R127H, p.A49A                    pathogenic, polymophism      EC1+CL       c.79G\>A                         p.V27I                             polymorphism                 TM1      1
  c.380G\>A, c.608T\>C                    p.R127H, p.I203T                   pathogenic, polymophism      CL+TM4       c.79G\>A, c.341A\>G              p.V27I, p.E114G                    polymorphism                 TM1+CL   1
  c.380G\>A, c.608T\>C                    p.R127H, p.I203T                   pathogenic, polymophism      CL+TM4       c.79G\>A                         p.V27I                             polymorphism                 TM1      1
  c.380G\>A                               p.R127H                            pathogenic                   CL           c.79G\>A                         p.V27I                             polymorphism                 TM1      4
  c.380G\>A                               p.R127H                            pathogenic                   CL           c.457G\>A                        p.V153I                            polymorphism                 TM3      1
  c.380G\>A                               p.R127H                            pathogenic                   CL           Nv                                                                                                        10
  c.416G\>A                               p.S139N                            pathogenic                   CL           c.79G\>A, c.341A\>G              p.V27I, p.E114G                    polymorphism                 TM1+CL   1
  c.416G\>A                               p.S139N                            pathogenic                   CL           Nv                                                                                                        1
  c.424_c.426del3                         p.del142F                          pathogenic                   TM3          c.79G\>A, c.341A\>G, c.109G\>A   p.V27I, p.E114G, p.V37I            polymorphisms, see note      TM1+CL   3
  c.424_c.426del3                         p.del142F                          pathogenic                   TM3          c.79G\>A, c.109G\>A              p.V27I, p.V37I                     polymorphisms, see note      TM1      1
  c.512_c.513insAACG                      frame-shift                        pathogenic                   EC2          c.79G\>A, c.368C\>A              p.V27I, p.T123N                    polymorphism, unclassified   TM1+CL   1
  c.512_c.513insAACG                      frame-shift                        pathogenic                   EC2          Nv                                                                                                        1
                                                                                                                                                                                                                                 
  unclassified variant                                                                                                                                                                                                           
  c.61G\>C, c.79G\>A                      p.G21R, p.V27I                     unclassified, polymorphism   NT+TM1       c.79G\>A, c.341A\>G              p.V27I, p.E114G                    polymorphism                 TM1+CL   1
  c.88A\>T                                p.I30F                             unclassified                 TM1          Nv                                                                                                        1
  c.93T\>G                                p.F31L                             unclassified                 TM1          c.79G\>A, c.341A\>G              p.V27I, p.E114G                    polymorphism                 TM1+CL   1
  c.187G\>T                               p.V63L                             unclassified                 EC1          Nv                                                                                                        2
  c.368C\>A, c.79G\>A                     p.T123N, p.V27I                    unclassified, polymorphism   CL+TM1       c.79G\>A, c.341A\>G              p.V27I, p.E114G                    polymorphism                 TM1+CL   1
  c.368C\>A, c.79G\>A                     p.T123N, p.V27I                    unclassified, polymorphism   CL+TM1       c.79G\>A                         p.V27I                             polymorphism                 TM1      3
  c.368C\>A                               p.T123N                            unclassified                 CL           c.79G\>A                         p.V27I                             polymorphism                 TM1      7
  c.368C\>A, c.608T\>C                    p.T123N, p.I203T                   unclassified, polymorphism   CL+TM4       c.79G\>A                         p.V27I                             polymorphism                 TM1      1
  c.458T\>C                               p.V153A                            unclassified                 EC2          c.608T\>C                        p.I203T                            polymorphism                 TM4      1
  c.571T\>C, c.592G\>A                    p.F191L, p.V198M                   unclassified                 TM4+TM4      c.79G\>A                         p.V27I                             polymorphism                 TM1      1
  c.583A\>G                               p.M195V                            unclassified                 TM4          Nv                                                                                                        1
  c.583A\>G                               p.M195V                            unclassified                 TM4          c.79G\>A, c.341A\>G              p.V27I, p.E114G                    polymorphism                 TM1+CL   1
  c.592G\>A, c.79G\>A, c.341A\>G          p.V198M, p.V27I, p.E114G           unclassified, polymorphism   TM4+TM1+CL   c.79G\>A, c.341A\>G              p.V27I, p.E114G                    polymorphism                 TM1+CL   1
  c.592G\>A, c.79G\>A                     p.V198M, p.V27I                    unclassified, polymorphism   TM4+TM1      c.79G\>A, c.341A\>G              p.V27I, p.E114G                    polymorphism                 TM1+CL   1
  c.592G\>A                               p.V198M                            unclassified                 TM4          c.79G\>A, c.341A\>G              p.V27I, p.E114G                    polymorphism                 TM1+CL   2
  c.475G\>A                               p.D159N                            unclassified                 EC2          Nv                                                                                               TM1+CL   1
  c644T\>A, c.79G\>A, c.341A\>G           p.I215N, p.V27I, p.E114G           unclassified, polymorphism   CT+TM1+CL    c.79G\>A, c.341A\>G              p.V27I, p.E114G                    polymorphism                 TM1+CL   1
  c.644T\>A                               p.I215N                            unclassified                 CT           c.608T\>C                        p.I203T                            polymorphism                 TM4      1
  c.109G\>A                               p.V37I                             see note                     TM1          c.109G\>A                        p.V37I                             see note                     TM1      23
  c.109G\>A                               p.V37I                             see note                     TM1          c.79G\>A, c.341A\>G              p.V27I, p.E114G                    polymorphism                 TM1+CL   29
  c.109G\>A                               p.V37I                             see note                     TM1          c.79G\>A                         p.V27I                             polymorphism                 TM1      10
  c.109G\>A                               p.V37I                             see note                     TM1          c.608T\>C                        p.I203T                            polymorphism                 TM4      3
  c.109G\>A                               p.V37I                             see note                     TM1          Nv                                                                                                        91
                                                                                                                                                                                                                                 
  polymorphism                                                                                                                                                                                                                   
  c.79G\>A, c.341A\>G                     p.V27I, p.E114G                    polymorphism                 TM1+CL       c.79G\>A, c.341A\>G              p.V27I, p.E114G                    polymorphism                 TM1+CL   90
  c.79G\>A                                p.V27I                             polymorphism                 TM1          c.79G\>A                         p.V27I                             polymorphism                 TM1      18
  c.79G\>A, c.341A\>G                     p.V27I, p.E114G                    polymorphism                 TM1+CL       c.79G\>A                         p.V27I                             polymorphism                 TM1      42
  c.79G\>A, c.341A\>G                     p.V27I, p.E114G                    polymorphism                 TM1+CL       c.341A\>G                        p.E114G                            polymorphism                          2
  c.79G\>A, c.341A\>G                     p.V27I, p.E114G                    polymorphism                 TM1+CL       c.457G\>A                        p.V153I                            polymorphism                 TM3      1
  c.79G\>A, c.341A\>G                     p.V27I, p.E114G                    polymorphism                 TM1+CL       c.608T\>C                        p.I203T                            polymorphism                 TM4      12
  c.79G\>A, c.341A\>G                     p.V27I, p.E114G                    polymorphism                 TM1+CL       Nv                                                                                                        387
  c.79G\>A                                p.V27I                             polymorphism                 TM1          c.608T\>C                        p.I203T                            polymorphism                 TM4      5
  c.79G\>A, c.608T\>C                     p.V27I                             polymorphism                 TM1+TM4      c.608T\>C                        p.I203T                            polymorphism                 TM4      1
  c.79G\>A                                p.V27I                             polymorphism                 TM1          Nv                                                                                                        202
  c.147C\>T                               p.A49A                             polymorphism                 EC1          Nv                                                                                                        1
  c.181A\>G                               p.K61K                             polymorphism                 EC1          Nv                                                                                                        1
  c.341A\>G                               p.E114G                            polymorphism                 CL           Nv                                                                                                        14
  c.438C\>T                               p.F146F                            polymorphism                 TM3          Nv                                                                                                        2
  c.608T\>C                               p.I203T                            polymorphism                 TM4          c.608T\>C                        p.I203T                            polymorphism                 TM4      3
  c.608T\>C                               p.I203T                            polymorphism                 TM4          Nv                                                                                                        28
                                                                                                                                                                                                                                 
  nv                                                                                                                   Nv                                                                                                        638
                                                                                                                                                                                                                                 
  total                                                                                                                                                                                                                          2063

nv: no variant

Note: p.V37I is controversy variant, see the discussion.

###### 

Prevalence of *GJB2*mutations in different areas of China

                        Number of NSHI   c.235delC allele   c.299_c.300delAT allele   c.176_c.191del16 allele   Uncommon mutant allele   total number of mutant alleles(%)                                                                 
  -------------- ------ ---------------- ------------------ ------------------------- ------------------------- ------------------------ ----------------------------------- --- ---- ----------- --- ---- ---------- --- ---- ----------- ------
  Jiangsu        102    26               10                 36 (35.3)                 12                        18                       42 (67.7)                           2   7    11 (17.7)   1   7    9 (14.5)   0   0    0           30.4
  Nei Mongol     115    30               5                  35 (30.4)                 14                        18                       46 (70.8)                           0   11   11 (16.9)   0   3    3 (4.6)    1   3    5 (7.7)     28.3
  Beijing        155    37               6                  43 (27.7)                 24                        13                       61 (76.3)                           0   10   10 (12.5)   0   0    0          0   9    9 (11.3)    25.8
  Hebei          64     14               3                  17 (26.6)                 7                         9                        23 (74.2)                           0   3    3 (9.7)     0   1    1 (3.2)    0   4    4 (12.9)    24.2
  Shanghai       31     7                1                  8 (25.8)                  3                         5                        11 (73.3)                           0   2    2 (13.3)    0   1    1 (6.7)    0   1    1 (6.7)     24.2
  Heilongjiang   36     5                4                  9 (25.0)                  1                         7                        9 (64.3)                            0   2    2 (14.3)    0   0    0          0   3    3 (21.4)    19.4
  Guangdong      77     15               4                  19 (24.7)                 10                        7                        27 (79.4)                           0   4    4 (11.8)    0   0    0          0   3    3 (8.8)     22.1
  Sichuan        109    17               8                  25 (22.9)                 10                        13                       33 (78.6)                           0   3    3 (7.1)     0   4    4 (9.5)    0   2    2 (4.8)     19.3
  Shanxi         57     11               2                  13 (22.8)                 4                         9                        17 (70.8)                           0   5    5 (20.8)    0   1    1 (4.2)    0   1    1 (4.2)     21.1
  Gansu          42     7                2                  9 (21.4)                  3                         5                        11 (68.8)                           0   3    3 (18.8)    0   0    0          0   2    2 (12.5)    19
  Jilin          57     12               0                  12 (21.1)                 7                         4                        18 (75.0)                           0   5    5 (21.0)    0   0    0          0   1    1 (4.0)     21.1
  Fujian         48     6                4                  10 (20.8)                 5                         4                        14 (87.5)                           0   1    1 (6.3)     0   0    0          0   1    1 (6.3)     16.7
  Ningxia        145    20               9                  29 (20.0)                 8                         14                       30 (61.2)                           1   3    5 (10.2)    0   4    4 (8.2)    0   10   10 (20.4)   16.9
  Xinjiang       136    19               8                  27 (19.9)                 9                         5                        23 (50.0)                           2   4    8 (17.4)    0   3    3 (6.5)    1   10   12 (26.1)   16.9
  Hubei          47     7                2                  9 (19.1)                  6                         2                        14 (87.5)                           0   0    0           0   0    0          0   2    2 (12.5)    17
  Yunnan         230    23               19                 42 (18.3)                 11                        14                       36 (55.4)                           1   3    5 (7.7)     1   2    4 (6.2)    1   18   20 (30.8)   14.1
  Guiyang        138    23               2                  25 (18.1)                 16                        9                        41 (85.4)                           0   6    6 (12.5)    0   0    0          0   1    1 (2.1)     17.4
  Henan          126    16               5                  21 (16.7)                 10                        8                        28 (75.7)                           0   5    5 (13.5)    0   0    0          0   4    4 (10.8)    14.7
  Tibet          118    0                19                 19 (16.1)                 0                         2                        2 (10.5)                            0   1    1 (5.3)     0   0    0          0   16   16 (84.2)   8.1
  Qinghai        56     5                3                  8 (14.3)                  1                         3                        5 (38.5)                            2   2    6 (46.2)    0   0    0          0   2    2 (15.4)    11.6
  Anhui          35     3                2                  5 (14.3)                  1                         4                        6 (75.0)                            0   1    1 (12.5)    0   1    1 (12.5)   0   0    0           11.4
  Shaanxi        52     3                2                  5 (9.6)                   1                         4                        6 (75.0)                            0   1    1 (12.5)    0   0    0          0   1    1 (12.5)    7.7
  Guangxi        87     1                5                  6 (6.9)                   1                         4                        6 (85.7)                            0   0    0           0   0    0          0   1    1 (14.3)    4
  total          2063   307              125                432                       164                       181                      345                                 8   82   90          2   27   29         3   95   98          17.9

homo: homozygous; het: hetrozygous; ^a^percentage of total mutant alleles identified.

Frame-shift and nonsense Pathogenic Mutations
---------------------------------------------

The c.235delC is the most prevalent mutation in the Chinese NSHI population with a total of 509 alleles (164 homozygous, 113 compound heterozygous with other pathogenic mutant alleles, and 68 one heterozygous allele only), followed by 98 c.299_c.300delAT mutant alleles (8 homozygotes, 76 compound heterozygotes, and 6 one allele heterozygotes), 31 c.176_c.191del16 mutant alleles (2 homozygous, 25 compound heterozygous and 2 with only one allele), and 12 c.35delG mutant alleles(2 homozygous, 3 compound heterozygous and 2 with only one allele) (Supplemental Table 1). The four prevalent mutations account for 88.0% (650/739) of all mutant alleles identified. Five novel mutations were identified in 20 patients; including two nonsense; p.W3X, p.Y152X, and 4 frame-shift truncation mutations; c.99delT, c.155--c.158 delTCTG, and c.512--c.513 insAACG. Among these, c.512--c.513insAACG occurs in 12 patients, including one homozygous from Yunnan. The novel truncation mutations account for only about 3.1% (23/739, Supplemental Table 1) of the overall *GJB2*mutant alleles. The most prevalent Caucasian mutation, c.35delG, was found in 2 homozygous, 3 compound heterozygous, and 5 single allele heterozygous patients. Among the patients with c.35delG, 70% of patients (7/10) are Uigur from Xinjiang area. The c.35insG mutation was found in 2 patients (both are Hui people) compound heterozygous with the c.235delC mutation. Other reported frame-shift mutations; 1 c.388--c.397del10 and 3 c.605--c.606ins46, as well as nonsense mutations; 3 p.E47X, account for a small fraction (1.0%) of *GJB2*mutant alleles. Overall, 92.6% (684/739) of the pathogenic mutations are frame-shift truncation or nonsense mutations, and they are predicted to cause loss of function of connexin 26. Only 6.9% (51/739) of the mutant alleles are reported missense mutations.

Reported missense pathogenic mutations
--------------------------------------

There are 8 reported missense pathogenic mutations and 1 in-frame deletion of 1 single amino acid, c.424_c.426del3 (p.del142F), which occurs in 4 heterozygous patients (Supplemental Table 1). The 8 missense mutations are p.G4D (3 heterozygous patients), p.R32C (one patient in compound heterozygosity with c.235delC), p.R143W (4 compound heterozygotes), p.T86R (all compound heterozygous, 6 with c.235delC and 1 with c.299_c.300delAT), p.R127H (one compound with p.Y152X, 31 single heterozygotes), p.S139N (2 single heterozygotes), p.E47K (one compound with c.299_c.300delAT), p.S85P (single heterozygote). All occur in an evolutionarily highly conserved region (Figure [2](#F2){ref-type="fig"}) \[[@B26],[@B29],[@B30]\].

![**Amino acid alignment of Connexin26 in different species**.](1479-5876-7-26-2){#F2}

Unclassified Variants
---------------------

Twelve unclassified missense variants were identified. The p.G21R is most likely to be pathogenic based on its highly evolutionarily conserved nature and the dramatic effect of the amino acid substitutions on structure and ionic strength. The p.I215N variant is located in the conserved region of C-terminal ion channel domain. Replacing the hydrophobic amino acid isoleucine with a hydrophilic amino acid asparagine in this conserved region is expected to cause detrimental effect. This variant is also in compound heterozygous with a novel pathogenic mutation, c.155_c.158delTCTG. Thus, it is likely to be pathogenic.

The missense variants, p.I30F, p.F31L, p.V63L, p.V153A, p.D159N, p.F191L, p.M195V, and p.V198M, do not involve drastic change in amino acid structure and polarity. They are all present as single heterozygous alleles without the presence of a second pathogenic mutant allele. Thus, their pathogenicity cannot be determined. Other changes of the same amino acids have been reported. For example, p.V63A has been reported as a novel variant, p.V153I and p.D159N were reported as a polymorphism \[[@B29]\]. The p.M195V and p.V198M, each occurs in two patients, without the second mutant allele. Each of the other variants occurs as heterozygous in one patient. None of these missense variants were detected in the control population.

Uncharacterized Novel Silent Variants
-------------------------------------

Several nucleotide substitutions do not result in amino acid change. These are p.A49A, p. K61K, p.F146F, and p.T186T (p.T186T is heterozygous with a single c.235delC). Although these nucleotide changes do not alter the encoded amino acids, we cannot exclude the possibility that they may activate an exonic splice enhancer and cause aberrant splicing. Alternatively, changes in triplet codon may affect the preference of codon usage or the stability of the mRNA, which in turn can affect the protein levels.

Genotypes and Carrier Frequency in the Normal Control Population
----------------------------------------------------------------

*GJB2*is a small gene but harbors many mutations. Thus, the carrier frequency of *GJB2*mutation in the Chinese population is not negligible. We sequenced the coding region of 301 normal control individuals of the Han ethnic group. Nine individuals were found to be heterozygous carriers of *GJB2*pathogenic mutations; three had the c.235delC, three had the c.299_c.300delAT, and the c.512_c.513insAACG, c.35delG, and p.E47X mutation have been detected in single individuals (see Supplemental Table 3). Thus, the carrier frequency of *GJB2*mutations in the control population is 3%.

Frequencies of missense variants in patient and control populations
-------------------------------------------------------------------

The frequencies of common missense variants such as p.V37I, p.V27I, p.I203T, p.T123N, p.E114G in patients, control, and other Asian populations were compared (see Supplemental Table 4 and Table 5). The pathogenic role of p.V37I has been controversial \[[@B24]-[@B26],[@B30]-[@B33]\]. It was found that the p.V37I allele frequency was significantly higher in the Han patient group (excluding all cases with two clearly pathogenic mutations) than in the control group (6.7% and 2.8% respectively,. p = 0.0003), supporting a pathogenic role of p.V37I. The allele frequencies of p.V27I, p.E114G, p.I203T, and p.T123N were higher in the control group than in the Han patient group (excluding all cases with two clearly pathogenic mutations), arguing against their pathogenic role (see Supplemental Table 4 and Table 5).

*GJB2*mutation spectra among different sub-ethnic groups in China
-----------------------------------------------------------------

As indicated in Table [2](#T2){ref-type="table"}, the frequency of *GJB2*mutations varies from 4% in Guangxi to 30.4% in Jiangsu. These results suggest that the variation in mutation frequencies may be due to ethnic diversity in various regions. The total population of China is 1.3 billion and sub-populations of Han, Tibetan, Hui, Man, Mon, minorities in Xinjiang, and minorities in South-western China are 1137.4 million, 5.4 million, 9.8 million, 10.7 million, 5.8 million, 10.8 million, and 57.1 million, respectively (<http://www.cnmuseum.com/intro/renkou_intro.asp>, <http://www.xzqh.org/quhua/index.htm>). We therefore analyzed the mutation frequencies in different sub-ethnic groups. As shown in Supplemental Table 6, Hui has the highest frequency of overall *GJB2*mutations, followed by Han and minorities in Xinjiang with 20.3, 19.1, and 15.3% respectively. Tibetan and the minorities in the Southwest have lower mutation frequencies, 9.4 and 5.0% respectively, similar to the frequencies observed in corresponding regions. The majority of mutations found in this study were found in the Han patient group (1640 cases) only except c.35 insG that was in compound heterozygous with c.235delC found in two Hui patients. The common Caucasian mutation, c.35delG was mainly detected in the minorities of Xinjiang, and accounted for almost half of the *GJB2*mutant alleles in minorities of Xinjiang (9 c.35delG/19 total mutant alleles). The finding of the c.35delG mutation in Xinjiang may be due in part to the close vicinity of Xinjiang to Russia and Eastern European countries, and possible admixture. The Maan sub-ethnic group also appears to have diverse *GJB2*mutation spectrum because mutations other than c.235delC account for more than one third of the mutant alleles. The three most common mutations c.235delC, c.299_c.300delAT, and c.176_c.191del16 account for 100% of *GJB2*mutations in 18 Mongolian individuals analyzed. However, the sample size is too small to be statistically significant.

Discussion
==========

Previous reports have suggested that the prevalence of *GJB2*mutations among different ethnic groups varies. In our patients, the most common Caucasian mutation, c.35delG was only found in 10 patients (seven of them were Uigur from Xinjiang). Instead, the c.235delC account for 68.9% of all *GJB2*mutant alleles in our Chinese study population. These results support that the c.235delC mutation in connexin 26 gene is the most prevalent mutation in most Asian populations, including Han Chinese \[[@B11],[@B24],[@B30],[@B34]\]. The results from this study indicate that analysis of four common mutations, c.235delC, c.299_c.300delAT, c.176_c.191del16, and 35delG can detect 88.0% (650/739) of *GJB2*mutations. In 13 regions of China, by analyzing these four mutations, we were able to identified at least one mutant allele in all studied patients with one or two *GJB2*mutations (see Table [2](#T2){ref-type="table"} and Supplemental Table 2). In contrast, mutations in the *GJB2*gene account for a variable proportion of the molecular etiology of NSHI in different regions and sub-ethnic groups in China. Our results have tremendous impact on the design of molecular diagnostic and carrier testing of NSHI families in China. For example, in addition to the three most common mutations of c.235delC, c.299_c.300delAT, c.176_c.191del16, for minorities in Xinjiang, testing of Caucasian c.35delG mutation should be included. In patients with Maan ethnic background, sequencing of the *GJB2*coding region should be offered, since the analysis of three common mutations detects only 71% of *GJB2*mutant alleles. In minorities from Southwest provinces, although the three most common mutations account for \>90% of all *GJB2*mutations, defects in *GJB2*gene account for only a small fraction (5%, Supplemental Table 2 and Table 6) of mutant alleles in NSHI patients. Thus, in these groups, analysis of other NSHI related genes should be pursued.

We recently reported that 7.8% of patients with autosomal recessive nonsyndromic hearing impairment in China were homozygous for the most common c.235delC mutation in *GJB2*gene and 8.5% of them carried one mutant allele of the c.235delC mutation \[[@B28]\]. Sequencing of the coding region of the *GJB2*gene reveals that 14.9% of the patients carry two pathogenic *GJB2*mutation and 6.1% carry only one mutant allele. These results are comparable to other reported studies \[[@B7],[@B11],[@B13],[@B24],[@B29],[@B30],[@B33]-[@B35]\]. The proportions of patients with *GJB2*mutations carrying only one mutant allele vary among different regions, different sub-ethnic groups, and different countries \[[@B7],[@B11],[@B13],[@B24],[@B29],[@B30],[@B33]-[@B35]\]. The observation that sequence analysis of *GJB2*gene in subjects with autosomal recessive NSHI results in a high number of patients with only one *GJB2*mutant allele has been puzzling \[[@B23]\]. Our unpublished data showed that no mutation were found in *GJB2*Exon1 and its splicing sequence among 851 deaf individuals from Central China in this cohort which suggested extremely low detection rate of *GJB2*Exon1 mutation among Chinese deaf population. For there is higher frequency of single heterozygous *GJB2*mutation detected in the deaf population than in the normal population in this study, the further more extensive study of sequence change in *GJB2*Exon1 or promoter area and 3\'-UTR, fragment deletion neighboring *GJB2*ORF region and digenic inheritance with other genes are already considered in this large Chinese deaf cohort for elucidating complex pathogenesis of *GJB2*gene to hearing impairment. We already added a paragraph in discussion. Thus, a digenic hypothesis was proposed and mutations in two other connexin (Cx) genes, *GJB6*for Cx30 and *GJB3*for Cx31 were studied \[[@B21],[@B22],[@B36]\]. In families with clear evidence of linkage to the DFNB1 locus, which contains two genes, *GJB2*and *GJB6*\[[@B6],[@B20]\], a common 309 kb deletion, involving the coding region *GJB6*gene upstream of *GJB2*gene has been identified and found to account for up to 10% of DFNB1 alleles in Caucasians \[[@B22]\]. We analyzed the deletion in *GJB6*gene in 372 patients from Inner Mongolia and central China, and deletions in *GJB6*gene were not detected. Similar studies of *GJB6*mutations in Taiwanese prelingual NSHI patients carrying one *GJB2*mutant allele also did not detect any deleterious mutations in *GJB6*, consistent with our results \[[@B30]\].

Although the spectrum of rare *GJB2*mutations varies among sub-ethnic groups and in different regions of China, the same most common c.235delC mutation is shared. This observation is in agreement with the reports from the studies of other Asian NSHI patients \[[@B10],[@B11],[@B24],[@B30],[@B34]\]. However, instead of c.299_c.300delAT being the second most prevalent mutation, p.G45E accounts for 16% of the Japanese *GJB2*mutations, while p.G4D accounts for 10.6% of Taiwanese *GJB2*mutant alleles \[[@B10],[@B30]\]. The p.G45E mutation was not detected in our patients. The p.G4D mutation accounts for only 0.3% of *GJB2*mutant alleles in Chinese NSHI patients and was recently reported in a US study \[[@B29],[@B30]\].

Among the 23 pathogenic mutations, 14 cause truncated connexin 26 proteins due to nonsense or frame-shift mutations, 8 are missense mutations, and one is a deletion of one amino acid. These mutations occur along the coding region. The truncation mutations account for 92.6% of the mutant alleles. Amino acids sequence homology alignment reveals that all missense mutations and unclassified variants occur at an evolutionarily conserved amino acid (Figure [2](#F2){ref-type="fig"}).

Three missense variants, p.V63L, p.V153A, and p.V198M, are located in extracelluar domain 1, 2, and transmembrane span 4, respectively, of connexin 26 protein. All these changes have not been reported in the Connexins and Deafness mutations database at <http://davinci.crg.es/deafness>. However, p.V63L has been found in 1 Taiwanese patient \[[@B30]\]. These three variants likely contribute to the pathogenesis of deafness, because (a) they were detected only in the patient group and not in 394 Japanese, 864 Taiwanese, 494 Korean and 301 Chinese (in this study) hearing normal subjects, and (b) they are evolutionarily conserved in xenopus, mouse, rat, sheep, orangutan, and human (Figure. [2](#F2){ref-type="fig"}). These variants were found in a heterozygous state in 4 unrelated patients who carried only one mutant allele.

The pathogenicity of p.V37I is controversial. In a recent multicenter study, the p.V37I mutation was found to be associated with mild to moderate hearing impairment (median 25--40 dB) \[[@B37]\]. Our study revealed that p.V37I with an allele frequency of 6.7% (185/2744) in the Han patient group (excluding all cases with two clearly pathogenic mutations) is significantly higher compared with that (2.8%;17/602) found in the control population (p = 0.0003, see Supplemental Table 4 and Table 5), supporting Wu\'s opinion to reassignment of p. V37I from an allele variant to a pathogenic mutation \[[@B38]\].

The p.T123N is an unclassified variant. It was counted as a mutation in Japanese group but a polymorphism in a Taiwanese study \[[@B10],[@B30]\]. We found a higher p.T123N allele frequency in the control group than in the patient group, suggesting that it may be neutral variant. However, its clinical implication is not clear at this time.

The results of this study provide a great potential benefit for the clinical application of genetic testing for deafness. Based upon our preliminary data of molecular epidemiology of hearing impairment in China \[[@B28],[@B39]-[@B41]\], Li has combined allele-specific PCR and universal array (ASPUA) methodologies for the detection of mutations causing hereditary hearing loss. It was employed for multiplex detection of 11 mutations in *GJB2*, *GJB3*, *SLC26A4*and mitochondrial DNA causing hereditary hearing loss \[[@B42]\]. Although this simple screening chip only include probes and primers for the c.35delG, c.176_c.191del16, c.235delC, c.299_c.300delAT mutations of *GJB2*gene, it can detect 88.0% (650/739) of *GJB2*mutations among these 2063 deaf individuals, meanwhile, up to 88.9% (384/432) of 432 patients confirmed to carry at least one *GJB2*mutation by sequencing in this study will be picked up by this fast screen method. The new methods for multiple mutation detection including ASPUA with capacity to test more gene loci have been under developed in our center, the data of this study will be crucial for the mutation selection in any new technology development for *GJB2*gene testing in Chinese population.

In summary, this study revealed a unique *GJB2*mutation spectrum in Chinese patients with nonsyndromic hearing impairment. The c.235delC mutation is the most frequent mutation in Chinese patients. Testing of four common mutations, c.235delC, c.299_c.300delAT, c.176_c.191del16, and c.35delG can detect 88.0% of the *GJB2*mutant alleles. However, in some regions or sub-ethnic groups, the *GJB2*mutations only account for a small fraction of the NSHI mutant alleles. In these regions, analysis of NSHI related genes is necessary. The molecular defects of more than 80% of the mutant alleles for NSHI in China remain to be identified.
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